Epalrestat

DRUG4 trials

Sponsors

Sun Yat-sen University, Maggie's Pearl, LLC, The Third Xiangya Hospital of Central South University, Haibo Shao

Conditions

Charcot-Marie-Tooth Disease (CMT)DiabetesHCC - Hepatocellular CarcinomaPhosphomannomutase 2 Congenital Disorder of GlycosylationPhosphomannomutase 2 DeficiencyPhosphomannomutase II Congenital Disorder of GlycosylationPhosphomannomutase II DeficiencyPmm2-CDG

Phase 2

Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer

TerminatedNCT03244358

Sun Yat-sen UniversityTriple Negative Breast Cancer

Start: 2017-03-01End: 2020-12-01Updated: 2021-01-29

Research of SORD-CMT Natural History and Epalrestat Treatment

Not yet recruitingNCT05777226

The Third Xiangya Hospital of Central South UniversityCharcot-Marie-Tooth Disease (CMT)

Start: 2023-04-30End: 2026-04-30Target: 30Updated: 2023-04-18

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

Not yet recruitingNCT07557914

Haibo ShaoDiabetes, HCC - Hepatocellular Carcinoma

Start: 2026-06-01End: 2029-02-01Target: 32Updated: 2026-06-03

Phase 3

Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

TerminatedNCT04925960

Maggie's Pearl, LLCPhosphomannomutase 2 Congenital Disorder of Glycosylation, Phosphomannomutase 2 Deficiency, Phosphomannomutase II Congenital Disorder of Glycosylation +2

Start: 2022-11-10End: 2025-02-28Updated: 2025-09-25